Nami Developing Targeted Nanoparticle Therapy for Advanced Forms of Ovarian Cancer

Nami Developing Targeted Nanoparticle Therapy for Advanced Forms of Ovarian Cancer
Nami Therapeutics is developing a new form of targeted therapy that aims to be more effective and less toxic than other treatments for advanced forms of ovarian cancer. The new therapy uses small particles (nanoparticles) that are specifically designed to deliver a toxic radioactive compound called holmium-166 (Ho-166) to ovarian cancer cells, while leaving healthy cells unharmed. Unlike currently-available ovarian cancer treatments that spread throughout the body, this new therapy remains confined to the abdominal cavity, targeting cancer cells that have already spread from the ovaries to the surrounding tissues. "That's where we want the radioactivity to stay," Xiuling Lu, acting CEO of Nami and associate professor of pharmaceutics at the University of Connecticut's School of Pharmacy, said in a press release. "We don't want it spreading throughout the body. It stays put in the region with the cancer cells." An additional advantage of Nami’s technology over current treatments is that its manufacturing process is safer, faster, and more efficient because technicians handle the radioactive compounds for shorter periods of time. "People know that making radioactive isotopes is hard. Nobody wants to handle that," Lu said. "Ours is a safe, effective, and far more economical process because our manufacturing uses non-radioactive materials and then simply requires a one-step conversion to make it radioactive." Nami is an early-phase startup company r
Subscribe or to access all post and page content.